The International Vaccine Institute or IVI and Bharat Biotech International Ltd or BBIL have begun the phase-II /III trials of global Chikungunya vaccine in Costa Rica. According to IVI, the maiden participant received Bharat Biotech’s Chikungunya vaccine candidate (BBV87) in a phase-II or III clinical trial in Costa Rica, heralding the beginning of a multi-country study led by IVI partnering with BBIL.
BBIL’s Chairman and Managing Director Krishna Ella said, “Epidemic preparedness is a vital step in public health care. Bharat Biotech’s vaccine candidate is an ingenious, well-researched vaccine, and we thank the first volunteer from Costa Rica for participating in this study. The IVI-led multi-country scale human trial has begun an important trial phase in furthering the evaluation of safety and immunogenicity. As a partner, we are committed towards GCCDP’s effort to realise a safe, efficacious vaccine that can help reduce Chikungunya disease burden the world over.”
Funded by CEPI or Coalition for Epidemic Preparedness Innovations, the study is supported by the Ind-CEPI mission of India’s Department of Biotechnology. IVI is progressing BBV87’s clinical development via a phase-II /III randomised and controlled trial for evaluating the safety and immunogenicity of a two-dose system of BBV87 Chikungunya vaccine conducted in healthy adults at nine clinical trial locations in five countries with Chikungunya.